{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:33:31Z","timestamp":1790721211544,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.anai.2022.01.026","type":"journal-article","created":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T20:41:29Z","timestamp":1643575289000},"page":"35-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["The adverse reactions to vaccines practice parameter 10 years on\u2014what have we learned?"],"prefix":"10.1016","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1321-8968","authenticated-orcid":false,"given":"John M.","family":"Kelso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4 Suppl 2","key":"10.1016\/j.anai.2022.01.026_bib0001","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S1081-1206(10)60350-X","article-title":"Adverse reactions to vaccines","volume":"103","author":"Kelso","year":"2009","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.anai.2022.01.026_bib0002","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaci.2012.04.003","article-title":"Adverse reactions to vaccines practice parameter 2012 update","volume":"130","author":"Kelso","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"1645","key":"10.1016\/j.anai.2022.01.026_bib0003","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2013.0433","article-title":"The contribution of vaccination to global health: past, present and future","volume":"369","author":"Greenwood","year":"2014","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"9","key":"10.1016\/j.anai.2022.01.026_bib0004","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1377\/hlthaff.2021.00619","article-title":"Vaccinations against COVID-19 may have averted up to 140,000 deaths in the United States","volume":"40","author":"Gupta","year":"2021","journal-title":"Health Aff (Millwood)"},{"issue":"6","key":"10.1016\/j.anai.2022.01.026_bib0005","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.anai.2017.03.010","article-title":"Vaccine allergy: a decade of experience from 2 large UK allergy centers","volume":"118","author":"Li","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.anai.2022.01.026_bib0006","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.jaip.2019.01.025","article-title":"Vaccine allergy? Skin testing and challenge at a tertiary pediatric hospital in Melbourne, Australia","volume":"7","author":"Cheung","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.anai.2022.01.026_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7005a1","article-title":"Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices, United States, 2021-22 influenza season","volume":"70","author":"Grohskopf","year":"2021","journal-title":"MMWR Recomm Rep"},{"issue":"8","key":"10.1016\/j.anai.2022.01.026_bib0008","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1586\/14760584.2014.933079","article-title":"Administering influenza vaccine to egg-allergic persons","volume":"13","author":"Kelso","year":"2014","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"10.1016\/j.anai.2022.01.026_bib0009","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.anai.2017.10.020","article-title":"Administration of influenza vaccines to egg-allergic recipients: a practice parameter update 2017","volume":"120","author":"Greenhawt","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/j.anai.2022.01.026_bib0010","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jaci.2013.11.020","article-title":"Food allergy: epidemiology, pathogenesis, diagnosis, and treatment","volume":"133","author":"Sicherer","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2022.01.026_bib0011","article-title":"Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2016-2017","volume":"138","year":"2016","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.anai.2022.01.026_bib0012","article-title":"Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2021-2022","volume":"148","year":"2021","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.anai.2022.01.026_bib0013","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.jaip.2015.03.011","article-title":"Ovalbumin content in the yellow fever vaccine","volume":"3","author":"Smith","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.anai.2022.01.026_bib0014","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1097\/INF.0000000000002625","article-title":"Yellow fever vaccination in EGG-allergic children","volume":"39","author":"Sharma","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.anai.2022.01.026_bib0015","unstructured":"YF-Vax Package Insert Sanofi Pasteur Inc., Swiftwater, PA 18370, USA; 2020."},{"issue":"8","key":"10.1016\/j.anai.2022.01.026_bib0016","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/S1473-3099(19)30355-X","article-title":"Yellow fever vaccine and egg allergy","volume":"19","author":"Cancado","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"42","key":"10.1016\/j.anai.2022.01.026_bib0017","doi-asserted-by":"crossref","first-page":"6539","DOI":"10.1016\/j.vaccine.2020.08.020","article-title":"Safety of yellow fever vaccine administration in confirmed egg-allergic patients","volume":"38","author":"Gerhardt","year":"2020","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.anai.2022.01.026_bib0018","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1016\/j.jaip.2021.06.050","article-title":"Single-dose yellow fever vaccination is well tolerated in egg-allergic children despite positive intradermal test to the vaccine","volume":"9","author":"B\u00e9dard","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.anai.2022.01.026_bib0019","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/0091-6749(93)90344-F","article-title":"Anaphylaxis to measles, mumps, and rubella vaccine mediated by IgE to gelatin","volume":"91","author":"Kelso","year":"1993","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2022.01.026_bib0020","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0091-6749(95)70304-7","article-title":"IgE antibody to gelatin in children with immediate-type reactions to measles and mumps vaccines","volume":"96","author":"Sakaguchi","year":"1995","journal-title":"J Allergy Clin Immunol"},{"issue":"6 Pt 1","key":"10.1016\/j.anai.2022.01.026_bib0021","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0091-6749(96)80191-6","article-title":"Food allergy to gelatin in children with systemic immediate-type reactions, including anaphylaxis, to vaccines","volume":"98","author":"Sakaguchi","year":"1996","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2022.01.026_bib0022","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0091-6749(97)70108-8","article-title":"IgE-mediated systemic reactions to gelatin included in the varicella vaccine","volume":"99","author":"Sakaguchi","year":"1997","journal-title":"J Allergy Clin Immunol"},{"issue":"2 Pt 1","key":"10.1016\/j.anai.2022.01.026_bib0023","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0091-6749(99)70490-2","article-title":"The gelatin story","volume":"103","author":"Kelso","year":"1999","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2022.01.026_bib0024","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.jaci.2012.02.038","article-title":"Relationship between red meat allergy and sensitization to gelatin and galactose-\u03b1-1,3-galactose","volume":"129","author":"Mullins","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2022.01.026_bib0025","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/j.jaci.2016.10.037","article-title":"Anaphylaxis after zoster vaccine: implicating alpha-gal allergy as a possible mechanism","volume":"139","author":"Stone","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"10.1016\/j.anai.2022.01.026_bib0026","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1001\/jama.2021.1967","article-title":"Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US-December 14, 2020-January 18, 2021","volume":"325","author":"Shimabukuro","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.anai.2022.01.026_bib0027","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.anai.2021.03.024","article-title":"Misdiagnosis of systemic allergic reactions to mRNA COVID-19 vaccines","volume":"127","author":"Kelso","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"11","key":"10.1016\/j.anai.2022.01.026_bib0028","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1001\/jamainternmed.2021.3779","article-title":"Safety evaluation of the second dose of messenger RNA COVID-19 vaccines in patients with immediate reactions to the first dose","volume":"181","author":"Krantz","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"9","key":"10.1016\/j.anai.2022.01.026_bib0029","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1016\/j.jaip.2021.06.010","article-title":"First-dose mRNA COVID-19 vaccine allergic reactions: limited role for excipient skin testing","volume":"9","author":"Wolfson","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"14","key":"10.1016\/j.anai.2022.01.026_bib0030","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1016\/j.vaccine.2020.02.046","article-title":"Immunization stress-related response\u2014redefining immunization anxiety-related reaction as an adverse event following immunization","volume":"38","author":"Gold","year":"2020","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.anai.2022.01.026_bib0031","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jaip.2021.01.022","article-title":"The COVID-19 pandemic in 2021: avoiding overdiagnosis of anaphylaxis risk while safely vaccinating the world","volume":"9","author":"Greenhawt","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"10.1016\/j.anai.2022.01.026_bib0032","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1016\/j.jaip.2021.04.025","article-title":"Ascertainment bias in anaphylaxis safety data of COVID-19 vaccines","volume":"9","author":"Hourihane","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"31","key":"10.1016\/j.anai.2022.01.026_bib0033","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1016\/j.vaccine.2007.02.064","article-title":"Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"25","author":"R\u03cbggeberg","year":"2007","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.anai.2022.01.026_bib0034","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.7326\/L21-0104","article-title":"Administration of a second dose of the moderna COVID-19 vaccine after an immediate hypersensitivity reaction with the first dose: two case reports","volume":"174","author":"Mustafa","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.anai.2022.01.026_bib0035","unstructured":"Interim clinical considerations for use of COVID-19 vaccines currently authorized in the United States. Available at: https:\/\/www.cdc.gov\/vaccines\/covid-19\/info-by-product\/clinical-considerations.html. Accessed November 1, 2021."},{"issue":"6576","key":"10.1016\/j.anai.2022.01.026_bib0036","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"Gilbert","year":"2022","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.anai.2022.01.026_bib0037","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/cea.12760","article-title":"Immediate-type hypersensitivity to polyethylene glycols: a review","volume":"46","author":"Wenande","year":"2016","journal-title":"Clin Exp Allergy"},{"issue":"5","key":"10.1016\/j.anai.2022.01.026_bib0038","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.jaip.2018.12.003","article-title":"Immediate hypersensitivity to polyethylene glycols and polysorbates: more common than we have recognized","volume":"7","author":"Stone","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2022.01.026_bib0039","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaci.2021.04.032","article-title":"Basophil reactivity to BNT162b2 is mediated by PEGylated lipid nanoparticles in patients with PEG allergy","volume":"148","author":"Troelnikov","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"10.1016\/j.anai.2022.01.026_bib0040","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1111\/all.14794","article-title":"Allergenic components of the mRNA-1273 vaccine for COVID-19: possible involvement of polyethylene glycol and IgG-mediated complement activation","volume":"76","author":"Klimek","year":"2021","journal-title":"Allergy"},{"issue":"9","key":"10.1016\/j.anai.2022.01.026_bib0041","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.25524","article-title":"Assessment of allergic and anaphylactic reactions to mRNA COVID-19 vaccines with confirmatory testing in a US Regional Health System","volume":"4","author":"Warren","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.anai.2022.01.026_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2020.106678","article-title":"Antibodies against polyethylene glycol in human blood: a literature review","volume":"102","author":"Hong","year":"2020","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"10","key":"10.1016\/j.anai.2022.01.026_bib0043","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1016\/j.jaip.2021.06.006","article-title":"The risk of allergic reaction to SARS-CoV-2 vaccines and recommended evaluation and management: a systematic review, meta-analysis, GRADE assessment, and international consensus approach","volume":"9","author":"Greenhawt","year":"2021","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120622000497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120622000497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:28:49Z","timestamp":1761053329000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120622000497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1081120622000497"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2022.01.026","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The adverse reactions to vaccines practice parameter 10 years on\u2014what have we learned?","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2022.01.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}